Engineered PRINT^® nanoparticles for controlled delivery of antigens and immunostimulants

Abstract

Particle replication in non-wetting templates (PRINT) is a novel nanoparticle platform that provides compositional flexibility with the ability to specify size and shape in formulating vaccines. The PRINT platform also offers manufacturing and cost advantages over traditional particle technologies. Across multiple antigen and adjuvant formulations, robust antibody and cellular responses have been achieved using PRINT particles in mouse models. Preclinical studies applying PRINT technology in the disease areas of influenza, malaria, and pneumonia are described in this commentary. The proof of principle studies pave the way toward significant cost-effective solutions to global vaccine supply needs.

Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs

“…17 Codelivery of antigens with adjuvants using particulate carriers can further boost the immune response. 18,19 Many immune stimulating agents such as alum, oil in water emulsions, various TLR/NLR agonists, etc. are being explored in clinical as well as preclinical studies as vaccine adjuvants.…”

Therapeutic lipid-coated hybrid nanoparticles against bacterial infections

“…In recent years, Particle Replication In Non-wetting Templates (PRINT), an advanced unique so lithography particle moulding process, has been gaining interest. [140][141][142][143] The PRINT process enables the specic design and large-scale synthesis of well-dened micro-and nanoparticles with uniformed size and shape. In addition, a double usage of spray-drying technique serves as a promising large-scale method to assemble lipids onto nanoparticle surfaces.…”

Enabling Vaccine Delivery Platforms and Adjuvants for Malaria

“…The adjuvant activity of this nanoemulsion is dependent on the nanodroplet structure and positive charge, which enables the penetration of the mucous layer, binding to cell membranes, and cellular uptake [124,131]. In mice, NanoStat TM has been shown to produce systemic and mucosal immune responses including MyD88-independent Ab responses and MyD88-dependent Th-1 and Th-17 cell-mediated responses [132]. While most of the published research (including a Phase I clinical [133]) is with NanoStat TM formulated for intranasal delivery, a formulation that contains the same components in proportions tailored for intramuscular administration is also available.…”